A Phase 1b Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Idelalisib in Subjects Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 07 Apr 2017
At a glance
- Drugs Idelalisib (Primary) ; Ruxolitinib
- Indications Myelofibrosis; Thrombocytosis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Gilead Sciences
- 04 Apr 2017 Status changed from recruiting to active, no longer recruiting.
- 21 Oct 2016 Planned End Date changed from 1 Jul 2018 to 1 Aug 2018.
- 21 Oct 2016 Planned primary completion date changed from 1 Mar 2017 to 1 Apr 2018.